Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
The Journal of Headache and Pain
Published in: The Journal of Headache and Pain 1/2019

Open Access 01-12-2019 | Migraine | Review article

Identifying and managing refractory migraine: barriers and opportunities?

Authors: Linda D’Antona, Manjit Matharu

Published in: The Journal of Headache and Pain | Issue 1/2019

Login to get access

Abstract

The term refractory migraine has been used to describe persistent headache that is difficult to treat or fails to respond to standard and/or aggressive treatments. This subgroup of migraine patients are generally highly disabled and experience impaired quality of life, despite optimal treatments. Several definitions and criteria for refractory migraine have been published, but as yet, an accepted or established definition is not available. This article reviews the published criteria and proposes a new set of criteria. The epidemiology, pathophysiology and management options are also reviewed.
Literature
1.
Headache Classification Subcommittee of The International Headache Society (2018) The international classification of headache disorders 3rd edition. Cephalalgia 38:1–211
2.
Reisman EE Jr (1952) The use of experimental suppositories in treating refractory migraine. Am Pract Dig Treat 3(4):308–310PubMed
3.
Goadsby PJ, Schoenen J, Ferrari MD, Silberstein SD, Dodick D (2006) Towards a definition of intractable headache for use in clinical practice and trials. Cephalalgia 26(9):1168–1170PubMedCrossRef
4.
Schulman EA, Lake AE 3rd, Goadsby PJ, Peterlin BL, Siegel SE, Markley HG et al (2008) Defining refractory migraine and refractory chronic migraine: proposed criteria from the refractory headache special interest section of the American headache society. Headache 48(6):778–782PubMedCrossRef
5.
Silberstein SD, Dodick DW, Pearlman S (2010) Defining the pharmacologically intractable headache for clinical trials and clinical practice. Headache 50(9):1499–1506PubMedCrossRef
6.
Martelletti P, Katsarava Z, Lampl C, Magis D, Bendtsen L, Negro A et al (2014) Refractory chronic migraine: a consensus statement on clinical definition from the European headache federation. J Headache Pain 15:47PubMedPubMedCentralCrossRef
7.
Schulman EA, Brahin EJ (2008) Refractory headache: historical perspective, need, and purposes for an operational definition. Headache 48(6):770–777PubMedCrossRef
8.
Saper J, Lake A 3rd, Lipton R (2007) Staging headache cases: reconciling the complexity of a case with the required intensity of treatment. Headache 47(1):90–93PubMedCrossRef
9.
Bigal ME, Lipton RB (2006) Modifiable risk factors for migraine progression. Headache 46(9):1334–1343PubMedCrossRef
10.
Tietjen GE, Brandes JL, Digre KB, Baggaley S, Martin VT, Recober A et al (2007) History of childhood maltreatment is associated with comorbid depression in women with migraine. Neurology 69(10):959–968PubMedCrossRef
11.
Loder E, Biondi D (2003) Disease modification in migraine: a concept that has come of age? Headache 43(2):135–143PubMedCrossRef
12.
Silberstein SD, Dodick DW, Saper J, Huh B, Slavin KV, Sharan A et al (2012) Safety and efficacy of peripheral nerve stimulation of the occipital nerves for the management of chronic migraine: results from a randomized, multicenter, double-blinded, controlled study. Cephalalgia 32(16):1165–1179PubMedCrossRef
13.
Saper JR, Dodick DW, Silberstein SD, McCarville S, Sun M, Goadsby PJ (2011) Occipital nerve stimulation for the treatment of intractable chronic migraine headache: ONSTIM feasibility study. Cephalalgia 31(3):271–285PubMedPubMedCentralCrossRef
14.
Dowson A, Mullen MJ, Peatfield R, Muir K, Khan AA, Wells C et al (2008) Migraine intervention with STARFlex technology (MIST) trial: a prospective, multicenter, double-blind, sham-controlled trial to evaluate the effectiveness of patent foramen ovale closure with STARFlex septal repair implant to resolve refractory migraine headache. Circulation 117(11):1397–1404PubMedCrossRef
15.
Katsarava Z, Buse DC, Manack AN, Lipton RB (2012) Defining the differences between episodic migraine and chronic migraine. Curr Pain Headache Rep 16(1):86–92PubMedCrossRef
16.
Diener HC, Bussone G, Van Oene JC, Lahaye M, Schwalen S, Goadsby PJ (2007) Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia 27(7):814–823PubMedCrossRef
17.
Aurora SK, Dodick DW, Turkel CC, DeGryse RE, Silberstein SD, Lipton RB et al (2010) OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia 30(7):793–803PubMedCrossRef
18.
Sacco S, Bendtsen L, Ashina M, Reuter U, Terwindt G, Mitsikostas DD et al (2019) European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. J Headache Pain 20(1):6PubMedPubMedCentralCrossRef
19.
20.
American Headache S (2019) The American headache society position statement on integrating new migraine treatments into clinical practice. Headache 59(1):1–18
21.
Dworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland CS, Farrar JT et al (2008) Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain 9(2):105–121PubMedCrossRef
22.
Pistoia F, Sacco S, Carolei A (2013) Behavioral therapy for chronic migraine. Curr Pain Headache Rep 17(1):304PubMedCrossRef
23.
Haywood KL, Mars TS, Potter R, Patel S, Matharu M, Underwood M (2018) Assessing the impact of headaches and the outcomes of treatment: a systematic review of patient-reported outcome measures (PROMs). Cephalalgia 38(7):1374–1386PubMedCrossRef
24.
Hareendran A, Mannix S, Skalicky A, Bayliss M, Blumenfeld A, Buse DC et al (2017) Development and exploration of the content validity of a patient-reported outcome measure to evaluate the impact of migraine- the migraine physical function impact diary (MPFID). Health Qual Life Outcomes 15(1):224PubMedPubMedCentralCrossRef
25.
Lambru G, Andreou AP, Guglielmetti M, Martelletti P (2018) Emerging drugs for migraine treatment: an update. Expert Opin Emerg Drugs 23(4):301–318PubMedCrossRef
26.
27.
Charles A (2018) The pathophysiology of migraine: implications for clinical management. Lancet Neurol 17(2):174–182PubMedCrossRef
28.
29.
30.
Burstein R (2001) Deconstructing migraine headache into peripheral and central sensitization. Pain 89(2–3):107–110PubMedCrossRef
31.
Meng ID, Cao L (2007) From migraine to chronic daily headache: the biological basis of headache transformation. Headache 47(8):1251–1258PubMedCrossRef
32.
Maleki N, Becerra L, Brawn J, Bigal M, Burstein R, Borsook D (2012) Concurrent functional and structural cortical alterations in migraine. Cephalalgia 32(8):607–620PubMedCrossRef
33.
Mainero C, Boshyan J, Hadjikhani N (2011) Altered functional magnetic resonance imaging resting-state connectivity in periaqueductal gray networks in migraine. Ann Neurol 70(5):838–845PubMedPubMedCentralCrossRef
34.
Schwedt TJ, Chong CD, Wu T, Gaw N, Fu Y, Li J (2015) Accurate classification of chronic migraine via brain magnetic resonance imaging. Headache 55(6):762–777PubMedPubMedCentralCrossRef
35.
Gormley P, Anttila V, Winsvold BS, Palta P, Esko T, Pers TH et al (2016) Meta-analysis of 375,000 individuals identifies 38 susceptibility loci for migraine. Nat Genet 48(8):856–866PubMedPubMedCentralCrossRef
36.
Lipton RB, Silberstein SD, Saper JR, Bigal ME, Goadsby PJ (2003) Why headache treatment fails. Neurology 60(7):1064–1070PubMedCrossRef
37.
Dodick DW (2008) Reflections and speculations on refractory migraine: why do some patients fail to improve with currently available therapies? Headache 48(6):828–837PubMedCrossRef
38.
39.
Rapoport A, Stang P, Gutterman DL, Cady R, Markley H, Weeks R et al (1996) Analgesic rebound headache in clinical practice: data from a physician survey. Headache 36(1):14–19PubMedCrossRef
40.
Breslau N, Davis GC (1992) Migraine, major depression and panic disorder: a prospective epidemiologic study of young adults. Cephalalgia 12(2):85–90PubMedCrossRef
41.
Breslau N, Merikangas K, Bowden CL (1994) Comorbidity of migraine and major affective disorders. Neurology 44(10 Suppl 7):S17–S22PubMed
42.
Baskin SM, Lipchik GL, Smitherman TA (2006) Mood and anxiety disorders in chronic headache. Headache 46(Suppl 3):S76–S87PubMedCrossRef
43.
Saper JR (2006) “are you talking to me?” confronting behavioral disturbances in patients with headache. Headache 46(Suppl 3):S151–S156PubMedCrossRef
44.
45.
Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ (1989) The Pittsburgh sleep quality index: a new instrument for psychiatric practice and research. Psychiatry Res 28(2):193–213PubMedCrossRef
46.
Miller S, Matharu MS (2014) Migraine is underdiagnosed and undertreated. Practitioner 258(1774):19–24 2-3PubMed
47.
Andrasik F (2010) Biofeedback in headache: an overview of approaches and evidence. Cleve Clin J Med 77(Suppl 3):S72–S76PubMedCrossRef
48.
Harris P, Loveman E, Clegg A, Easton S, Berry N (2015) Systematic review of cognitive behavioural therapy for the management of headaches and migraines in adults. Br J Pain 9(4):213–224PubMedPubMedCentralCrossRef
49.
Holroyd KA, Cottrell CK, O'Donnell FJ, Cordingley GE, Drew JB, Carlson BW et al (2010) Effect of preventive (beta blocker) treatment, behavioural migraine management, or their combination on outcomes of optimised acute treatment in frequent migraine: randomised controlled trial. BMJ 341:c4871PubMedPubMedCentralCrossRef
50.
51.
52.
Rabe K, Pageler L, Gaul C, Lampl C, Kraya T, Foerderreuther S et al (2013) Prednisone for the treatment of withdrawal headache in patients with medication overuse headache: a randomized, double-blind, placebo-controlled study. Cephalalgia 33(3):202–207PubMedCrossRef
53.
Woldeamanuel YW, Rapoport AM, Cowan RP (2015) The place of corticosteroids in migraine attack management: a 65-year systematic review with pooled analysis and critical appraisal. Cephalalgia 35(11):996–1024PubMedCrossRef
54.
Palamar D, Uluduz D, Saip S, Erden G, Unalan H, Akarirmak U (2015) Ultrasound-guided greater occipital nerve block: an efficient technique in chronic refractory migraine without aura? Pain Physician 18(2):153–162PubMed
55.
Inan LE, Inan N, Karadas O, Gul HL, Erdemoglu AK, Turkel Y et al (2015) Greater occipital nerve blockade for the treatment of chronic migraine: a randomized, multicenter, double-blind, and placebo-controlled study. Acta Neurol Scand 132(4):270–277PubMedCrossRef
56.
Dilli E, Halker R, Vargas B, Hentz J, Radam T, Rogers R et al (2015) Occipital nerve block for the short-term preventive treatment of migraine: a randomized, double-blinded, placebo-controlled study. Cephalalgia 35(11):959–968PubMedCrossRef
57.
Rosen N, Marmura M, Abbas M, Silberstein S (2009) Intravenous lidocaine in the treatment of refractory headache: a retrospective case series. Headache 49(2):286–291PubMedCrossRef
58.
59.
Miller S, Watkins L, Matharu M (2016) Long-term outcomes of occipital nerve stimulation for chronic migraine: a cohort of 53 patients. J Headache Pain 17(1):68PubMedPubMedCentralCrossRef
60.
Lambru G, Trimboli M, Palmisani S, Smith T, Al-Kaisy A (2016) Safety and efficacy of cervical 10 kHz spinal cord stimulation in chronic refractory primary headaches: a retrospective case series. J Headache Pain 17(1):66PubMedPubMedCentralCrossRef
Metadata
Title
Identifying and managing refractory migraine: barriers and opportunities?
Authors
Linda D’Antona
Manjit Matharu
Publication date
01-12-2019
Publisher
Springer Milan
Published in
The Journal of Headache and Pain / Issue 1/2019
Print ISSN: 1129-2369
Electronic ISSN: 1129-2377
DOI
https://doi.org/10.1186/s10194-019-1040-x

Other articles of this Issue 1/2019

The Journal of Headache and Pain 1/2019 Go to the issue

Research article

C-fibers may modulate adjacent Aδ-fibers through axon-axon CGRP signaling at nodes of Ranvier in the trigeminal system

Research article

Advanced visual network and cerebellar hyperresponsiveness to trigeminal nociception in migraine with aura

Review article

Trigeminal neuralgia secondary to multiple sclerosis: from the clinical picture to the treatment options

Review article

Therapeutic novelties in migraine: new drugs, new hope?

Letter to the Editor

Letter to the editor regarding European Headache Federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention

Research article

Real-world treatment patterns and patient-reported outcomes in episodic and chronic migraine in Japan: analysis of data from the Adelphi migraine disease specific programme